Citations

Clear

439 citation(s) found for "Stone, M".

Association of Granulomatosis With Polyangiitis (Wegener's) With HLA–DPB1*04 and SEMA6A Gene Variants: Evidence From Genome‐Wide Analysis
Roshandel, Delnaz , Sherva, Richard , Lu, Emily Y., Kung, Tabitha, Carrington, Keisha, Zhang, Steven S., Pulit, Sara L. , Ripke, Stephan , Carette, Simon , Dellaripa, Paul F., Edberg, Jeffrey C., Hoffman, Gary S., Langford, Carol A. , Mahr, Alfred , Clair, E. William St. , Seo, Philip , Stone, John H., Ytterberg, Steven R. , Raychaudhuri, Soumya , Bakker, Paul I. W. de , Farrer, Lindsay A. , Siminovitch, Katherine, Xie, Gang , Sherva, Richard , Monach, Paul A. , Ripke, Stephan , Dellaripa, Paul F. , Khalidi, Nader , Specks, Ulrich , Spiera, Robert , Amos, Christopher I. , Merkel, Peter A. , Mahr, Alfred

Mayo Clinic

Arthritis & Rheumatism | June 5, 2013 | Volume: 65 | Issue: 9 | Pages: 2457-2468

10.1002/art.38036 | PMID 23740775 Get It

ObjectiveTo identify genetic determinants of granulomatosis with polyangiitis (Wegener's) (GPA).MethodsWe carried out a genome‐wide association study (GWAS) of 492 GPA cases and 1,506 healthy controls (white subjects of European descent), followed by replication analysis of the most strongly associated signals in an independent cohort of 528 GPA cases and 1,228 controls.ResultsGenome‐wide significant associations were identified in 32 single‐nucleotide polymorphic (SNP) markers across the HLA region, the majority of which were located in the HLA–DPB1 and HLA–DPA1 genes encoding the class II major histocompatibility complex (MHC) DPβ chain 1 and DPα chain 1 proteins, respectively. Peak association signals in these 2 genes, emanating from SNPs rs9277554 (for DPβ chain 1) and rs9277341 (DPα chain 1) were strongly replicated in an independent cohort (in the combined analysis of the initial cohort and the replication cohort, P = 1.92 × 10−50 and 2.18 × 10−39, respectively). Imputation of classic HLA alleles and conditional analyses revealed that the SNP association signal was fully accounted for by the classic HLA–DPB1*04 allele. An independent single SNP, rs26595, near SEMA6A (the gene for semaphorin 6A) on chromosome 5, was also associated with GPA, reaching genome‐wide significance in a combined analysis of the GWAS and replication cohorts (P = 2.09 × 10−8).ConclusionWe identified the SEMA6A and HLA–DP loci as significant contributors to risk for GPA, with the HLA–DPB1*04 allele almost completely accounting for the MHC association. These two associations confirm the critical role of immunogenetic factors in the development of GPA.
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Marcucci, Guido , Maharry, Kati , Metzeler, Klaus H. , Wu, Yue-Zhong, Mrózek, Krzysztof , Kohlschmidt, Jessica, Whitman, Susan P., Schwind, Sebastian , Becker, Heiko , Eisfeld, Ann‐Kathrin , Carroll, Andrew J. , Powell, Bayard L., Kolitz, Jonathan E. , Garzon, Ramiro , Stone, Richard M. , Bloomfield, Clara D. , Volinia, Stefano , Nicolet, Deedra , Mendler, Jason H. , Caligiuri, Michael A.

Mayo Clinic

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 17 | Pages: 2086-2093

10.1200/jco.2012.45.6228 | PMID 23650424 Get It

Purpose To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.
Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
Holbrook, Janet T. , Tibbs, Andrea K., Allen, Nancy B., Davis, John C. , Hoffman, Gary S., McCune, W. Joseph, Clair, E. William St. , Petri, Michelle , Stone, John H., Merkel, Peter A. , Lo, Grace H. , Specks, Ulrich , Spiera, Robert

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 142 | Issue: 8 | Pages: 620-626

10.7326/0003-4819-142-8-200505030-00011 | PMID 15838068 Get It

Quality of Care in Patients with Diabetes
Weir, Sam, Stone, Robert, Hodgson, Stephen F., Fleming, Barbara , Levy, Philip Thaler

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 137 | Issue: 1 | Pages: 71

10.7326/0003-4819-137-1-200207020-00021 | PMID 12093254 Get It

High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Stiff, Patrick J., Veum-Stone, Judith, Lazarus, Hillard M., Ayash, Lois, Edwards, John R., Keating, Armand, Klein, John P., Oblon, David J., Shea, Thomas C., Thomé, Stephan, Horowitz, Mary M., Stiff, Patrick J., Veum-Stone, Judith, Lazarus, Hillard M., Ayash, Lois, Edwards, John R., Keating, Armand, Klein, John P., Oblon, David J., Shea, Thomas C., Thomé, Stephan, Horowitz, Mary M.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 133 | Issue: 7 | Pages: 504-515

10.7326/0003-4819-133-7-200010030-00009 | PMID 11015163 Get It

Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
Finkielman, Javier D., Schroeder, Darrell R. , Hoffman, Gary S., Clair, E. William St. , Davis, John C. , McCune, W. Joseph, Lears, Andrea, Ytterberg, Steven R. , Hummel, Amber M., Viss, Margaret A., Peikert, Tobias, Stone, John H. , Merkel, Peter A. , Spiera, Robert , Specks, Ulrich , Schroeder, Darrell

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 147 | Issue: 9 | Pages: 611-619

10.7326/0003-4819-147-9-200711060-00005 | PMID 17975183 Get It

Bilateral Pulmonary Emboli Secondary to Indwelling Hemodialysis Reliable Outflow Catheter
Coan, Kathryn E., O’Donnell, Mark E., Fankhauser, Grant T. , Bodnar, Zachary, Chandrasekaran, Krishnaswamy , Stone, William M.

Mayo Clinic

Vascular and Endovascular Surgery | April 8, 2013 | Volume: 47 | Issue: 4 | Pages: 317-319

10.1177/1538574413484973 | PMID 23567802 Get It

We present a 33-year-old dialysis-dependent female who presented with new onset split second heart sound. Following a failed left upper extremity dialysis fistula, a right upper extremity hemodialysis reliable outflow (HeRO) graft was performed in 2011. Her subsequent cadaveric renal transplant had delayed function necessitating concurrent use of hemodialysis. However, as renal function improved, hemodialysis was discontinued. Two weeks following transplantation, the HeRO graft occluded. Subsequent clinical and radiological assessment confirmed widespread pulmonary emboli. Following cessation of hemodialysis and subsequent HeRO graft occlusion, removal was deemed appropriate to reduce further thromboembolic phenomenon. Right atrial thrombi are complications associated with central venous catheters. However, their actual incidence varies significantly. Right heart thromboemboli are associated with a 4% to 6% pulmonary embolism rate. Katzman et al assessed 38 patients who underwent HeRO graft and reported 1 (2.6%) patient with right atrial emboli and likely pulmonary embolism. Although thrombotic complications remain rare, consideration of graft removal should always be evaluated particularly in the absence of an alternative thrombotic source.
Response to Letter Regarding Article, “Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (A
Rosner, Gregg, Kirtane, Ajay J. , Généreux, Philippe, Cristea, Ecaterina , Weisz, Giora, Parise, Helen , Fahy, Martin, Stone, Gregg W. , Lansky, Alexandra J. , Mehran, Roxana , Gersh, Bernard J.

Mayo Clinic

Circulation | October 29, 2012 | Volume: 126 | Issue: 18 | Pages: No page available

10.1161/circulationaha.112.137752 Get It

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Mrózek, Krzysztof , Marcucci, Guido , Maharry, Kati , Becker, Heiko , Whitman, Susan P., Metzeler, Klaus H. , Schwind, Sebastian , Wu, Yue-Zhong, Kohlschmidt, Jessica, Pettenati, Mark J., Heerema, Nyla A. , Block, AnneMarie W., Patil, Shivanand R., Baer, Maria R. , Kolitz, Jonathan E. , Moore, Joseph O. , Carroll, Andrew J. , Stone, Richard M. , Larson, Richard A. , Bloomfield, Clara D. , Nicolet, Deedra , Larson, Richard A

Mayo Clinic

Journal of Clinical Oncology | September 18, 2012 | Volume: 30 | Issue: 36 | Pages: 4515-4523

10.1200/jco.2012.43.4738 | PMID 22987078 Get It

Purpose To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML). Patients and Methods We analyzed 1,550 adults with primary AML, treated on Cancer and Leukemia Group B first-line trials, who had pretreatment cytogenetics and, for cytogenetically normal patients, mutational status of NPM1, CEBPA, and FLT3 available. We compared complete remission (CR) rates, disease-free survival (DFS), and overall survival (OS) among patients classified into the four ELN genetic groups (favorable, intermediate-I, intermediate-II, adverse) separately for 818 younger (age < 60 years) and 732 older (age ≥ 60 years) patients. Results The percentages of younger versus older patients in the favorable (41% v 20%; P < .001), intermediate-II (19% v 30%; P < .001), and adverse (22% v 31%; P < .001) genetic groups differed. The favorable group had the best and the adverse group the worst CR rates, DFS, and OS in both age groups. Both intermediate groups had significantly worse outcomes than the favorable but better than the adverse group. Intermediate-I and intermediate-II groups in older patients had similar outcomes, whereas the intermediate-II group in younger patients had better OS but not better CR rates or DFS than the intermediate-I group. The prognostic significance of ELN classification was confirmed by multivariable analyses. For each ELN group, older patients had worse outcomes than younger patients. Conclusion The ELN classification clearly separates the genetic groups by outcome, supporting its use for risk stratification in clinical trials. Because they have different proportions of genetic alterations and outcomes, younger and older patients should be reported separately when using the ELN classification.